Nanoparticle pharmacokinetic profiling in vivo using magnetic resonance imaging Export

@article{citeulike:4123710, abstract = {Contrast agents targeted to molecular markers of disease are currently being developed with the goal of identifying disease early and evaluating treatment effectiveness using noninvasive imaging modalities such as MRI. Pharmacokinetic profiling of the binding of targeted contrast agents, while theoretically possible with MRI, has thus far only been demonstrated with more sensitive imaging techniques. Paramagnetic liquid perfluorocarbon nanoparticles were formulated to target alphavbeta3-integrins associated with early atherosclerosis in cholesterol-fed rabbits to produce a measurable signal increase on magnetic resonance images after binding. In this work, we combine quantitative information of the in vivo binding of this agent over time obtained by means of MRI with blood sampling to derive pharmacokinetic parameters using simultaneous and individual fitting of the data to a three compartment model. A doubling of tissue exposure (or area under the curve) is obtained with targeted as compared to control nanoparticles, and key parameter differences are discovered that may aid in development of models for targeted drug delivery. Magn Reson Med 60:1353-1361, 2008. {\copyright} 2008 Wiley-Liss, Inc.}, address = {Consortium for Translational Research in Advanced Imaging and Nanomedicine, Washington University, St Louis, Missouri; Department of Biomedical Engineering, Washington University, St. Louis, Missouri; Philips Medical Systems, Andover, Massachusetts; Analytical Chemistry Group, University of Missouri Research Reactor, Columbia, Missouri}, author = {Neubauer, Anne M. and Sim, Hoon and Winter, Patrick M. and Caruthers, Shelton D. and Williams, Todd A. and Robertson, J. David and Sept, David and Lanza, Gregory M. and Wickline, Samuel A.}, citeulike-article-id = {4123710}, citeulike-linkout-0 = {http://dx.doi.org/10.1002/mrm.21795}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/19025903}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=19025903}, citeulike-linkout-3 = {http://www3.interscience.wiley.com/cgi-bin/abstract/121535712/ABSTRACT}, doi = {10.1002/mrm.21795}, issn = {1522-2594}, journal = {Magnetic Resonance in Medicine}, keywords = {alpha-nu-beta3-integrin, atherosclerosis, ccne-grant, mri, pharmacokinetics, sccne}, number = {6}, pages = {1353--1361}, posted-at = {2009-07-27 16:34:36}, priority = {2}, title = {Nanoparticle pharmacokinetic profiling in vivo using magnetic resonance imaging}, url = {http://dx.doi.org/10.1002/mrm.21795}, volume = {60}, year = {2008} }

TY - JOUR ID - citeulike:4123710 L3 - citeulike-article-id:4123710 N2 - Contrast agents targeted to molecular markers of disease are currently being developed with the goal of identifying disease early and evaluating treatment effectiveness using noninvasive imaging modalities such as MRI. Pharmacokinetic profiling of the binding of targeted contrast agents, while theoretically possible with MRI, has thus far only been demonstrated with more sensitive imaging techniques. Paramagnetic liquid perfluorocarbon nanoparticles were formulated to target alphavbeta3-integrins associated with early atherosclerosis in cholesterol-fed rabbits to produce a measurable signal increase on magnetic resonance images after binding. In this work, we combine quantitative information of the in vivo binding of this agent over time obtained by means of MRI with blood sampling to derive pharmacokinetic parameters using simultaneous and individual fitting of the data to a three compartment model. A doubling of tissue exposure (or area under the curve) is obtained with targeted as compared to control nanoparticles, and key parameter differences are discovered that may aid in development of models for targeted drug delivery. Magn Reson Med 60:1353-1361, 2008. © 2008 Wiley-Liss, Inc. IS - 6 JF - Magnetic Resonance in Medicine SN - 1522-2594 AD - Consortium for Translational Research in Advanced Imaging and Nanomedicine, Washington University, St Louis, Missouri; Department of Biomedical Engineering, Washington University, St. Louis, Missouri; Philips Medical Systems, Andover, Massachusetts; Analytical Chemistry Group, University of Missouri Research Reactor, Columbia, Missouri EP - 1361 TI - Nanoparticle pharmacokinetic profiling in vivo using magnetic resonance imaging VL - 60 SP - 1353 KW - alpha-nu-beta3-integrin KW - atherosclerosis KW - ccne-grant KW - mri KW - pharmacokinetics KW - sccne AU - Neubauer, Anne AU - Sim, Hoon AU - Winter, Patrick AU - Caruthers, Shelton AU - Williams, Todd AU - Robertson, David AU - Sept, David AU - Lanza, Gregory AU - Wickline, Samuel PY - 2008/// UR - http://dx.doi.org/10.1002/mrm.21795 ER -